NP-137 is under clinical development by Netris Pharma and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NP-137’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NP-137 is under development for the treatment of advanced pancreatic ductal adenocarcinoma, uterine cancer, endometrial carcinoma, cervix carcinoma, colon carcinoma, hepatocellular carcinoma and solid tumors including Head and Neck, Melanoma, Non-Small Cell Lung Cancer, Urothelial and other tumor types.. It is administered as an infusion through intravenous route. The drug candidate is a humanized monoclonal IgG1 antibody, which acts by targeting netrin-1 ligand. It was also under development for the treatment of hematologic malignancies.
Netris Pharma overview
Netris Pharma is a clinical-stage biopharmaceutical company that develops anti-cancer therapeutic molecules, essentially monoclonal antibodies. The company develops drugs using a novel and unique approach targeting dependence receptors. The company’s lead product, NP137, is a humanized monoclonal antibody of IgG1 isotype that acts against netrin-1, a dependence receptor ligand. It is developing NP137 for the treatment of all advanced tumors; endometrial and cervical cancer; non-small cell lung cancer; head and neck, colon and urothelial cancers; and liver and pancreatic cancers. Netris Pharma is also developing a pipeline of drugs targeting diverse ligands of dependence receptors. The company collaborates with academic institutions, and research and clinical partners including Leon Berard, Hospices Civils De Lyon, and Grenoble Alpes. The company is the first spin-off of Centre Leon Berard and the Cancer Research Center of Lyon. Netris Pharma is headquartered in Lyon, Rhone Alpes, France.
For a complete picture of NP-137’s drug-specific PTSR and LoA scores, buy the report here.